Abstract
BackgroundPD-(L)1 immune checkpoint blockade (ICB) therapy yields objective responses in 15-25% of patients with bladder cancer (BC), suggesting that tumor-associated resistance mechanisms undermine their efficacy.1-6 We previously identified two gene...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
